Aprea TherapeuticsAPRE -7.07%30 EBIT per Share is $-1.62 as of Mar. 2026. GuruFocus rates APRE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,180 Biotechnology companies, Aprea Therapeutics ranks better than 88.98% on this metric.
Aprea Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.23.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.62.
During the past 3 years, the average EBIT per Share Growth Rate was 55.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 51.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Aprea Therapeutics's EBIT per Share or its related term are showing as below:
APRE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -30.4 Med: 47 Max: 58
Current: 55.2
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Aprea Therapeutics was 58.00% per year. The lowest was -30.40% per year. And the median was 47.00% per year.
APRE's 3-Year EBIT Growth Rate is ranked better than 88.98% of 1180
companies
in the Biotechnology industry
Industry Median: 15.55
vs APRE: 55.20
Aprea Therapeutics (NAS:APRE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Aprea Therapeutics EBIT per Share Related Terms
Aprea Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Aprea Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.62
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprea Therapeutics (APRE) has a EBIT per Share of $-1.62 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aprea Therapeutics and its competitors. According to the industry distribution chart, Aprea Therapeutics ranks #130 out of 1180 companies in the Biotechnology industry, placing it in the top 11%.
Is Aprea Therapeutics' EBIT per Share too high?
Aprea Therapeutics' current EBIT per Share is $-1.62. Based on the distribution chart, Aprea Therapeutics ranks #130 out of 1180 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aprea Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' EBIT per Share compare to JSPR and CVKD?
According to the Biotechnology industry distribution chart, Aprea Therapeutics ranks #130 out of 1180 companies for EBIT per Share. This places Aprea Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,180 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aprea Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprea Therapeutics's current EBIT per Share is $-1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current EBIT per Share of $-1.62. The current EBIT per Share is $-1.62. Aprea Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current EBIT per Share is $-1.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
30GF Score
Get the complete analysis for APRE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APRE has been successfully added to your 
